Academic Journal
Immediate results of treatment of patients with metastatic uveal melanoma using isolated liver chemoperfusion. The first domestic experience ; Непосредственные результаты лечения пациентов с метастатической увеальной меланомой методом изолированной химиоперфузии печени. Первый отечественный опыт
| العنوان: | Immediate results of treatment of patients with metastatic uveal melanoma using isolated liver chemoperfusion. The first domestic experience ; Непосредственные результаты лечения пациентов с метастатической увеальной меланомой методом изолированной химиоперфузии печени. Первый отечественный опыт |
|---|---|
| المؤلفون: | A. Kaprin D., V. Unguryan M., L. Petrov O., S. Ivanov A., Yu. Pobedintseva A., E. Filimonov V., E. Kruglov A., N. Falaleeva A., V. Nazarova V., K. Orlova V., I. Utyashev A., А. Каприн Д., В. Унгурян М., Л. Петров О., С. Иванов А., Ю. Побединцева А., Е. Филимонов В., Е. Круглов А., Н. Фалалеева А., В. Назарова В., К. Орлова В., И. Утяшев А. |
| المصدر: | Meditsinskiy sovet = Medical Council; № 20 (2021); 117-123 ; Медицинский Совет; № 20 (2021); 117-123 ; 2658-5790 ; 2079-701X |
| بيانات النشر: | REMEDIUM GROUP Ltd. |
| سنة النشر: | 2021 |
| المجموعة: | Medical Council (E-Journal) / Медицинский Совет |
| مصطلحات موضوعية: | uveal melanoma, isolated liver chemoperfusion, liver metastases, melphalan, regional treatment, stage IV, progression, увеальная меланома, изолированная химиоперфузия печени, метастазы в печени, мелфалан, регионарное лечение, стадия IV, прогрессирование |
| الوصف: | Introduction. Uveal melanoma is the most common primary intraocular tumor in adults. Despite some achievements in primary tumor treatment, 50% of patients develop distant metastases in various times (3 years to decades). Hematogenous spread is typical for uveal melanoma, and in 90% of the cases liver is the target. Median survival of patients with liver metastases is 4 to 9 months according to various researchers. And the result of treatment is extremely poor, unlike the results of skin melanoma treatment.The aim is to evaluate the immediate results of treatment of patients with uveal melanoma metastatic to the liver using isolated hepatic perfusion technique.Materials and methods. Considering a high risk of developing a metastatic liver disease in patients with uveal melanoma, local therapy is particularly interesting. This article describes the results of 10 metastatic uveal melanoma patients’ Isolated Hepatic Perfusion (IHP) Treatment. IHP was conducted using the standard methods with 100 mg of Melphalan for 60 min.Results and discussion. IHP treatment shows low complication rate. The data for response assessment is available on 9 out of 10 patients, because 10th patient received this treatment less than a month ago. Follow-ups a month after 9 patients underwent IHP showed an objective response to treatment in 6 patients (complete response in 1, partial response in 5 patients).Conclusion. The use of isolated liver chemoperfusion in a small group of patients according to the standard procedure allowed achieving an immediate response in 67% of cases. ; Введение. Увеальная меланома является наиболее распространенной первичной внутриглазной опухолью у взрослых. Несмотря на достигнутые успехи в лечении первичной опухоли, у 50% пациентов в различные сроки (от 3 лет до десятилетий) развиваются отдаленные метастазы. Увеальная меланома метастазирует гематогенным путем, в 90% случаев поражается печень. Медиана продолжительности жизни при развитии метастатических проявлений в печени по данным разных авторов в среднем ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| Relation: | https://www.med-sovet.pro/jour/article/view/6588/5971; Egan K.M., Seddon J.M., Glynn R.J., Gragoudas E.S., Albert D.M. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32(4):239–251. https://doi.org/10.1016/0039-6257(88)90173-7.; Kincaid M.C. Uveal melanoma. Cancer Control. 1998;5(4):299–309. https://doi.org/10.1177/107327489800500401.; Seregard S. Posterior uveal melanoma. The Swedish perspective. Acta Ophthalmol Scand. 1996;74(4):315–329. https://doi.org/10.1111/j.1600-0420.1996.tb00701.x.; The collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS). JAMA Ophthalmol. 2001;119(5):670–676. https://doi.org/10.1001/archopht.119.5.670.; Folberg R. Tumor progression in ocular melanomas. J Invest Dermatol. 1993;100(3):3265–3315. Available at: https://pubmed.ncbi.nlm.nih.gov/8440916/.; Shields J.A., Shields C.L., Donoso L.A. Management of posterior uveal melanoma. Surv Ophthalmol. 1991;36(3):161–195. https://doi.org/10.1016/0039-6257(91)90001-v.; Gragoudas E.S., Egan K.M., Seddon J.M., Glynn R.J., Walsh S.M., Finn S.M. et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98(3):383–389. https://doi.org/10.1016/s0161-6420(91)32285-1.; Kath R., Hayungs J., Bornfeld N., Sauerwein W., Hoffken K., Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72(7):2219–2223. https://doi.org/10.1002/1097-0142(19931001)72:73.0.co;2-j.; Rajpal S., Moore R., Karakousis C.P. Survival in metastatic ocular melanoma. Cancer. 1983;52(2):334–336. https://doi.org/10.1002/1097-0142(19830715)52:23.0.co;2-e.; Eskelin S., Pyrhonen S., Hahka-Kemppinen M., Tuomaala S., Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97(2):465–475. https://doi.org/10.1002/cncr.11113.; Alexander H.R., Libutti S.K., Pingpank J.F., Steinberg S.M., Bartlett D.L., Helsabeck C., Beresneva T. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9(17):6343–6349. Available at: https://pubmed.ncbi.nlm.nih.gov/14695133/.; Olofsson R., Ny L., Eilard M.S., Rizell M., Cahlin C., Stierner U. et al. Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials. 2014;15:317. https://doi.org/10.1186/1745-6215-15-317.; Alexander H.R., Libutti S.K., Bartlett D.L., Puhlmann M., Fraker D.L., Bachenheimer L.C. A phase I–II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6(8):3062–3070. Available at: https://clincancerres.aacrjournals.org/content/6/8/3062.long.; Alexander H.R., Bartlett D.L., Libutti S.K., Fraker D.L., Moser T., Rosenberg S.A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16(4):1479–1489. https://doi.org/10.1200/JCO.1998.16.4.1479.; Bates D.A., Mackillop W.J. The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro. Br J Cancer. 1990;62(2):183–188. https://doi.org/10.1038/bjc.1990.257.; van der Zee J., Kroon B.B., Nieweg O.E., van de Merwe S.A., Kampinga H.H. Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion. Eur J Cancer. 1997;33(10):1546–1550. https://doi.org/10.1016/s0959-8049(97)00116-0.; Hafstrom L.R., Holmberg S.B., Naredi P.L., Lindner P.G., Bengtsson A., Tidebrant G., Schersten T.S. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 1994;3(2):103–108. https://doi.org/10.1016/0960-7404(94)90005-1.; Rothbarth J., Pijl M.E.J., Vahrmeijer A.L., Hartgrink H.H., Tijl F.G.J, Kuppen P.J.K. et al. Isolated hepatic perfusion with high dose melphalan for the treatment of metastatic colorectal cancer confined to the liver. Br J Surg. 2003;90(11):1391–1397. https://doi.org/10.1002/bjs.4308.; Vahrmeijer A.L., van Dierendonck J.H., Keizer H.J., Beijnen J.H., Tollenaar R.A., Pijl M.E. et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer. 2000;82(9):1539–1546. https://doi.org/10.1054/bjoc.2000.1175.; Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214. https://doi.org/10.1002/1097-0142(19810101)47:13.0.co;2-6.; Aoyama T., Mastrangelo M.J., Berd D., Nathan F.E., Shields C.L., Shields J.A. et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89(7):1561–1568. https://doi.org/10.1002/1097-0142(20001001)89:73.0.co;2-r.; Bedikian A.Y., Legha S.S., Mavligit G., Carrasco C.H., Khorana S., Plager C. et al. Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76(9):1665–1670. https://doi.org/10.1002/1097-0142(19951101)76:93.0.co;2-j.; Becker J.C., Terheyden P., Kampgen E., Wagner S., Neumann C., Schadendorf D. et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002;87(8):840–845. https://doi.org/10.1038/sj.bjc.6600521.; Kivela T., Suciu S., Hansson J., Kruit W.H., Vuoristo M.S., Kloke O. et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39(8):1115–1120. https://doi.org/10.1016/s0959-8049(03)00132-1.; Nathan F.E., Berd D., Sato T., Shield J.A., Shields C.L., De Potter P. et al. BOLD + interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res. 1997;16(2):201–208. Available at: https://pubmed.ncbi.nlm.nih.gov/9261748/.; Pyrhonen S., Hahka-Kemppinen M., Muhonen T., Nikkanen V., Eskelin S., Summanen P. et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95(11):2366–2372. https://doi.org/10.1002/cncr.10996.; Egerer G., Lehnert T., Max R., Naeher H., Keilholz U., Ho A.D. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol. 2001;6(1):25–28. https://doi.org/10.1007/pl00012075.; Leyvraz S., Spataro V., Bauer J., Pampallona S., Salmon R., Dorval T. et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15(7):2589–2595. https://doi.org/10.1200/JCO.1997.15.7.2589.; Mavligit G.M., Charnsangavej C., Carrasco C.H., Patt Y.Z., Benjamin R.S., Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. J Am Med Assoc. 1988;260(7):974–976. https://doi.org/10.1001/jama.1988.03410070102037.; Richardson P.G., Murakami C., Jin Z., Warren D., Momtaz P., Hoppensteadt D. et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100(13):4337–4343. https://doi.org/10.1182/blood-2002-04-1216.; Ben-Shabat I., Belgrano V., Ny L., Nilsson J., Lindner P., Olofsson Bagge R. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Ann Surg Oncol. 2016;23(4):1327–1234. https://doi.org/10.1245/s10434-015-4982-5.; Eggermont A.M., van Ijken M.G., van Etten B., van der Sijp J.R., ten Hagen T.L., Wiggers T., et al. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology. 2000;47(33):776–781. Available at: https://pubmed.ncbi.nlm.nih.gov/10919031/.; van Ijken M.G., de Bruijn E.A., de Boeck G., ten Hagen T.L., van der Sijp J.R., Eggermont A.M. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloonatheter techniques: a pharmacokinetic study in pigs. Ann Surg. 1998;228(6):763–770. https://doi.org/10.1097/00000658-199812000-00007.; Rothbarth J., Pijl M.E.J., Tollenaar R.A.E.M., Tijl F., Ivancev G., Mulder G.J. et al. An experimental minimally invasive perfusion technique for the treatment of liver metastases. Eur J Surg Oncol. 2003;29(9):757–763. https://doi.org/10.1016/j.ejso.2003.08.004.; Vogl T.J., Koch S.A., Lotz G., Gebauer B., Willinek W., Engelke C. et al. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. Cardiovasc Intervent Radiol. 2017;40(6):864–872. https://doi.org/10.1007/s00270-017-1588-2.; Carr M.J., Sun J., Cohen J.B., Liu J., Serdiuk A.A., Stewart S.R. et al. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. Cancer Control. 2020;27(1):1073274820983019. https://doi.org/10.1177/1073274820983019.; https://www.med-sovet.pro/jour/article/view/6588 |
| DOI: | 10.21518/2079-701X-2021-20-117-123 |
| الاتاحة: | https://www.med-sovet.pro/jour/article/view/6588 https://doi.org/10.21518/2079-701X-2021-20-117-123 |
| Rights: | Authors publishing their articles in this journal shall agree to the following:Authors reserve the copyright to the work and grant the journal a license to publish the work for the first time Creative Commons Attribution License (CC BY), which allows other persons to distribute this work with the obligatory preservation of references to the authors of the original work and the original publication in this journal.Authors reserve the right to conclude separate contractual arrangements regarding the non-exclusive distribution of the work version in the form published here (for example, posting it in the institute’s repository, publication in a book), with reference to its original publication in this journal.Authors have the right to post work on the Internet (for example, in the institute’s repository or personal website) before and during the process of considering it by this journal, as this can result in a productive discussion and more references to this work. ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию.Авторы имеют право размещать работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу. (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.54102BA2 |
| قاعدة البيانات: | BASE |
| DOI: | 10.21518/2079-701X-2021-20-117-123 |
|---|